Our vision is to restore health for all people living with immune diseases. Inspired by the promise of helping patients reclaim their lives, our immune pathway strategy aims to deliver transformational and accessible therapies for patients, redefining a standard of care that demands durable, symptom-free remission. In 2023, we made progress in the following areas:
Maternal fetal health
We are investigating nipocalimab as the potential first noninvasive intervention and potential first treatment for pregnancies at risk of early-onset severe hemolytic disease of the fetus and newborn (HDFN), a rare disease where alloantibodies from the pregnant person cross the placenta, attacking fetal red blood cells that can result in the death of the fetus. Our Phase 2 open-label study that enrolled 13 patients demonstrated 54% of live births at or after gestational age of 32 weeks without the need for an intrauterine transfusion, compared to the historic reference point of 10%, which was derived from published and unpublished data. Our Phase 3 pivotal study is ongoing.
Plaque psoriasis
We progressed a potential new advanced treatment in the convenience of a pill that could offer a new option for patients living with moderate to severe plaque psoriasis. The first positive results of our Phase 2b clinical trial for JNJ-2113 in severe plaque psoriasis were shared at the World Congress of Dermatology. JNJ-2113 in psoriasis is the first and only targeted oral peptide that is engineered to selectively block the IL-23 receptor, which is known to activate an inflammatory response. This investigational treatment has the potential to change the immunology treatment landscape and improve lives for millions of patients living with plaque psoriasis.
